191 related articles for article (PubMed ID: 26259553)
21. Molecular form and subcellular distribution of acid beta-galactosidase in fibroblasts from patients with GM1 gangliosidosis, Morquio B disease and galactosialidosis.
Takiyama N; Itoh K; Shimmoto M; Nishimoto J; Inui K; Sakuraba H; Suzuki Y
Brain Dev; 1997 Mar; 19(2):126-30. PubMed ID: 9105659
[TBL] [Abstract][Full Text] [Related]
22. A case of galactosialidosis with a homozygous Q49R point mutation.
Matsumoto N; Gondo K; Kukita J; Higaki K; Paragison RC; Nanba E
Brain Dev; 2008 Oct; 30(9):595-8. PubMed ID: 18396002
[TBL] [Abstract][Full Text] [Related]
23. Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis.
Suzuki Y; Ichinomiya S; Kurosawa M; Ohkubo M; Watanabe H; Iwasaki H; Matsuda J; Noguchi Y; Takimoto K; Itoh M; Tabe M; Iida M; Kubo T; Ogawa S; Nanba E; Higaki K; Ohno K; Brady RO
Ann Neurol; 2007 Dec; 62(6):671-5. PubMed ID: 17994547
[TBL] [Abstract][Full Text] [Related]
24. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
[TBL] [Abstract][Full Text] [Related]
25. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
[TBL] [Abstract][Full Text] [Related]
26. Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities.
Suzuki Y; Ogawa S; Sakakibara Y
Perspect Medicin Chem; 2009 May; 3():7-19. PubMed ID: 19812739
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of C-5a-chain extended derivatives of 4-epi-isofagomine: Powerful β-galactosidase inhibitors and low concentration activators of GM1-gangliosidosis-related human lysosomal β-galactosidase.
Thonhofer M; Weber P; Santana AG; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Bioorg Med Chem Lett; 2016 Mar; 26(5):1438-42. PubMed ID: 26838810
[TBL] [Abstract][Full Text] [Related]
28. Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis.
Caciotti A; Donati MA; Boneh A; d'Azzo A; Federico A; Parini R; Antuzzi D; Bardelli T; Nosi D; Kimonis V; Zammarchi E; Morrone A
Hum Mutat; 2005 Mar; 25(3):285-92. PubMed ID: 15714521
[TBL] [Abstract][Full Text] [Related]
29. Lysosomal accumulation of Trk protein in brain of GM₁ -gangliosidosis mouse and its restoration by chemical chaperone.
Takamura A; Higaki K; Ninomiya H; Takai T; Matsuda J; Iida M; Ohno K; Suzuki Y; Nanba E
J Neurochem; 2011 Aug; 118(3):399-406. PubMed ID: 21574998
[TBL] [Abstract][Full Text] [Related]
30. Galactosialidosis: historic aspects and overview of investigated and emerging treatment options.
Annunziata I; d'Azzo A
Expert Opin Orphan Drugs; 2017; 5(2):131-141. PubMed ID: 28603679
[TBL] [Abstract][Full Text] [Related]
31. Lysosomal multienzyme complex: pros and cons of working together.
Bonten EJ; Annunziata I; d'Azzo A
Cell Mol Life Sci; 2014 Jun; 71(11):2017-32. PubMed ID: 24337808
[TBL] [Abstract][Full Text] [Related]
32. Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.
Tatano Y; Takeuchi N; Kuwahara J; Sakuraba H; Takahashi T; Takada G; Itoh K
J Med Invest; 2006 Feb; 53(1-2):103-12. PubMed ID: 16538002
[TBL] [Abstract][Full Text] [Related]
33. Cathepsin A deficiency in galactosialidosis: studies of patients and carriers in 16 families.
Kleijer WJ; Geilen GC; Janse HC; van Diggelen OP; Zhou XY; Galjart NJ; Galjaard H; d'Azzo A
Pediatr Res; 1996 Jun; 39(6):1067-71. PubMed ID: 8725271
[TBL] [Abstract][Full Text] [Related]
34. Concise syntheses of potent chaperone drug candidates, N-octyl-4-epi-β-valinenamine (NOEV) and its 6-deoxy derivative, from (+)-proto-quercitol.
Kuno S; Takahashi A; Ogawa S
Carbohydr Res; 2013 Mar; 368():8-15. PubMed ID: 23314299
[TBL] [Abstract][Full Text] [Related]
35. Transient high-level expression of beta-galactosidase after transfection of fibroblasts from GM1 gangliosidosis patients with plasmid DNA.
Balestrin RC; Baldo G; Vieira MB; Sano R; Coelho JC; Giugliani R; Matte U
Braz J Med Biol Res; 2008 Apr; 41(4):283-8. PubMed ID: 18392450
[TBL] [Abstract][Full Text] [Related]
36. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.
Bonten EJ; Campos Y; Zaitsev V; Nourse A; Waddell B; Lewis W; Taylor G; d'Azzo A
J Biol Chem; 2009 Oct; 284(41):28430-28441. PubMed ID: 19666471
[TBL] [Abstract][Full Text] [Related]
37. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
38. Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Model system for revealing the intracellular transport of normal and mutated lysosomal enzymes.
Naganawa Y; Itoh K; Shimmoto M; Kamei S; Takiguchi K; Doi H; Sakuraba H
Biochem J; 1999 Jun; 340 ( Pt 2)(Pt 2):467-74. PubMed ID: 10333491
[TBL] [Abstract][Full Text] [Related]
39. Protective protein/cathepsin A loss in cultured cells derived from an early-infantile form of galactosialidosis patients homozygous for the A1184-G transition (Y395C mutation).
Itoh K; Shimmoto M; Utsumi K; Mizoguchi N; Miharu N; Ohama K; Sakuraba H
Biochem Biophys Res Commun; 1998 Jun; 247(1):12-7. PubMed ID: 9636645
[TBL] [Abstract][Full Text] [Related]
40. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.
Takai T; Higaki K; Aguilar-Moncayo M; Mena-Barragán T; Hirano Y; Yura K; Yu L; Ninomiya H; García-Moreno MI; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
Mol Ther; 2013 Mar; 21(3):526-32. PubMed ID: 23337983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
